Tuesday, February 23, 2016 5:03:00 AM PDT | VentureDeal
Cambridge, Massachusetts -- Biotechnology company Avrobio has received an undisclosed amount of seed stage venture capital investment.
Avrobio Is developing what it calls "step-change cell and gene therapies targeting cancer and rare disease." The company hopes to utilize the convergence of cell and gene therapies to accelerate scientific breakthroughs. Accomplice made the investment. The company said it would use the funding to accelerate development of its two novel cell and gene therapies by mid-2016 for acute myeloid leukemia and Fabry disease.
Email Page | Print Page
Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?
Start your Free 14 Day Trial now – no obligation or credit card required.
